Restoring long-term potentiation impaired by amyloid-beta oligomers: Comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists

Brain Research Bulletin

Volumn 96, Issue , 2013, Pages 28-38

  Kroker, Katja S ^a   Moreth, Jens ^a   Kussmaul, Lothar ^a   Rast, Georg ^a   Rosenbrock, Holger ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Amyloid oligomer; Donepezil; LTP; Nicotinic acetylcholine receptor

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; DONEPEZIL; NICOTINIC AGENT; OLIGOMER; TC 1827; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPAL CA1 REGION; LEARNING; LONG TERM POTENTIATION; MALE; MEMORY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT;

ACETYLCHOLINESTERASE INHIBITOR; ALZHEIMER'S DISEASE; AMYLOID-Β OLIGOMER; DONEPEZIL; LTP; NICOTINIC ACETYLCHOLINE RECEPTOR;

ACETYLCHOLINESTERASE; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHOLINESTERASE INHIBITORS; HIPPOCAMPUS; INDANS; LONG-TERM POTENTIATION; MALE; NICOTINIC AGONISTS; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC;

EID: 84878426402     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2013.04.006     Document Type: Article

References (142)

1. 1-42 modulation of Akt phosphorylation via α7 nAChR and NMDA receptors. Neurobiology of Aging 2008, 29:992-1001.
2. Alkondon M., Albuquerque E.X. The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex. Progress in Brain Research 2004, 145:109-120.
3. Alkondon M., Pereira E.F.R., Eisenberg H.M., Albuquerque E.X. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. Journal of Neuroscience 1999, 19:2693-2705.
4. Aramakis V.B., Metherate R. Nicotine selectively enhances NMDA receptor-mediated synaptic transmission during postnatal development in sensory neocortex. Journal of Neuroscience 1998, 18:8485-8495.
5. Balducci C., Beeg M., Stravalaci M., Bastone A., Sclip A., Biasini E., Tapella L., Colombo L., Manzoni C., Borsello T., Chiesa R., Gobbi M., Salmona M., Forloni G. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:2295-2300.
6. Barak S., Arad M., De Levie A., Black M.D., Griebel G., Weiner I. Pro-cognitive and antipsychotic efficacy of the α7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology 2009, 34:1753-1763.
7. Bashir Z.I., Alford S., Davies S.N., Randall A.D., Collingridge G.L. Long-term potentiation of NMDA receptor-mediated synaptic transmission in the hippocampus. Nature 1991, 349:156-158.
8. Birks J.S., Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2003, 3:CD001190.
9. Biton B., Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., Lanneau C., Santamaria R., Chesney F., Leonardon J., Granger P., Debono M.W., Bohme G.A., Sgard F., Besnard F., Graham D., Coste A., Oblin A., Curet O., Vige X., Voltz C., Rouquier L., Souilhac J., Santucci V., Gueudet C., Francon D., Steinberg R., Griebel G., Oury-Donat F., George P., Avenet P., Scatton B. SSR180711, a novel selective α7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007, 32:1-16.
10. Bliss T.V.P., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
11. Bohme G.A., Letchworth S.R., Piot-Grosjean O., Gatto G.J., Obinu M.-C., Caldwell W.S., Laville M., Brunel P., Pellerin R., Leconte J.-P., Genevois-Borella A., Dubedat P., Mazadier M., Pradier L., Bencherif M., Benavides J. In vitro and in vivo characterization of TC-1827 a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity. Drug Development and Research 2004, 62:26-40.
12. Broersen K., Rousseau F., Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. Alzheimer's Research & Therapy 2010, 2(12-).
13. Buccafusco J.J., Letchworth S.R., Bencherif M., Lippiello P.M. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends in Pharmacological Sciences 2005, 26:352-360.
14. Buchs P.A., Muller D. Induction of long-term potentiation is associated with major ultrastructural changes of activated synapses. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:8040-8045.
15. Catalano S.M., Dodson E.C., Henze D.A., Joyce J.G., Krafft G.A., Kinney G.G. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Current Topics in Medicinal Chemistry 2006, 6:597-608.
16. Cavus I., Teyler T. Two forms of long-term potentiation in area CA1 activate different signal transduction cascades. Journal of Neurophysiology 1996, 76:3038-3047.
17. Chan W.K., Wong P.T., Sheu F.S. Frontal cortical α7 and α4β2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology 2007, 52:1641-1649.
18. Chen L., Yamada K., Nabeshima T., Sokabe M. α7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 2006, 50:254-268.
19. Chen Q.S., Wei W.Z., Shimahara T., Xie C.W. Alzheimer amyloid β-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiology of Learning and Memory 2002, 77:354-371.
20. Cincotta S.L., Yorek M.S., Moschak T.M., Lewis S.R., Rodefer J.S. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Current Opinion in Investigational Drugs 2008, 9:47-56.
21. Collingridge G.L., Kehl S.J., McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. The Journal of Physiology 1983, 334:33-46.
22. Costa-Mattioli M., Sossin W.S., Klann E., Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009, 61:10-26.
23. Courtney C., Farrell D., Gray R., Hills R., Lynch L., Sellwood E., Edwards S., Hardyman W., Raftery J., Crome P., Lendon C., Shaw H., Bentham P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004, 363:2105-2115.
24. Decker H., Jürgensen S., Adrover M.F., Brito-Moreira J., Bomfim T.R., Klein W.L., Epstein A.L., De Felice F.G., Jerusalinsky D., Ferreira S.T. N-Methyl-d-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. Journal of Neurochemistry 2010, 115:1520-1529.
25. 2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:3269-3274.
26. Diniz B.S., Pinto J.A.J., Gonzaga M.L., Guimarães F.M., Gattaz W.F., Forlenza O.V. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience 2009, 259:248-256.
27. Fabian-Fine R., Skehel P., Errington M.L., Davies H.A., Sher E., Stewart M.G., Fine A. Ultrastructural distribution of the α7 nicotinic acetylcholine receptor subunit in rat hippocampus. Journal of Neuroscience 2001, 21:7993-8003.
28. Ferreira S.T., Klein W.L. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiology of Learning and Memory 2011, 96:529-543.
29. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Molecular Pharmacology 1992, 41:31-37.
30. Frankiewicz T., Potier B., Bashir Z.I., Collingridge G.L., Parsons C.G. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. British Journal of Pharmacology 1996, 117:689-697.
31. Freir D.B., Fedriani R., Scull D., Smith I.M., Selkoe D.J., Walsh D.M., Regan C.M. Aβ oligomers inhibit synapse remodeling necessary for memory consolidation. Neurobiology of Aging 2011, 32:2211-2218.
32. Freir D.B., Herron C.E. Inhibition of L-type voltage dependent calcium channels causes impairment of long-term potentiation in the hippocampal CA1 region in vivo. Brain Research 2003, 967:27-36.
33. Frey U., Krug M., Reymann K.G., Matthies H. Anisomycin an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Research 1988, 452:57-65.
34. Ge S., Dani J.A. Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. Journal of Neuroscience 2005, 25:6084-6091.
35. Geerts H. Ispronicline (Targacept). Current Opinion in Investigational Drugs 2006, 7:60-69.
36. Geerts H. α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease. Expert Opinion on Investigational Drugs 2012, 21:59-65.
37. Ghosh S. Meeting report: Alzheimer's Association International Conference 2012. Drugs of the Future 2012, 37:663-670.
38. Goto Y., Niidome T., Akaike A., Kihara T., Sugimoto H. Amyloid β-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. Biochemical and Biophysical Research Communications 2006, 351:259-265.
39. Graef S., Schönknecht P., Sabri O., Hegerl U. Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology 2011, 215:205-229.
40. Gray R., Rajan A.S., Radcliffe K.A., Yakehiro M., Dani J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996, 83:713-716.
41. Grecksch G., Matthies H. Two sensitive periods for the amnesic effect of anisomycin. Pharmacology Biochemistry and Behavior 1980, 12:663-665.
42. Grinevich V.P., Papke R.L., Lippiello P.M., Bencherif M. Atypical antipsychotics as noncompetitive inhibitors of α4β2 and α7 neuronal nicotinic receptors. Neuropharmacology 2009, 57:183-191.
43. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nature Reviews. Molecular Cell Biology 2007, 8:101-112.
44. Hajós M., Rogers B.N. Targeting α7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Current Pharmaceutical Design 2010, 16:538-554.
45. Haupt C., Leppert J., Rönicke R., Meinhardt J., Yadav J.K., Ramachandran R., Ohlenschläger O., Reymann K.G., Görlach M., Fändrich M. Structural basis of β-amyloid-dependent synaptic dysfunctions. Angewandte Chemie (International Edition in English) 2012, 51:1576-1579.
46. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., Stachowiak E.K., Stachowiak M.K., Papke R.L., Lippiello P.M., Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochemical Pharmacology 2009, 78:803-812.
47. Haydar S.N., Dunlop J. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Current Topics in Medicinal Chemistry 2010, 10:144-152.
48. Helou R., Rhalimi M. Cholinesterase inhibitors and the risk of pulmonary disorders in hospitalized dementia patients. Journal of Population Therapeutics and Clinical Pharmacology 2010, 17:e379-e389.
49. Hernandez R.K., Farwell W., Cantor M.D., Lawler E.V. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. Journal of the American Geriatrics Society 2009, 57:1997-2003.
50. Huang E.P. Synaptic plasticity: going through phases with LTP. Current Biology 1998, 8:R350-R352.
51. Hynd M.R., Scott H.L., Dodd P.R. Glutamate NMDA receptor NR1 subunit mRNA expression in Alzheimer's disease. Journal of Neurochemistry 2001, 78:175-182.
52. Hynd M.R., Scott H.L., Dodd P.R. Differential expression of N-methyl-d-aspartate receptor NR2 isoforms in Alzheimer's disease. Journal of Neurochemistry 2004, 90:913-919.
53. Izquierdo L.A., Barros D.M., Vianna M.R., Coitinho A., deDavid e Silva T., Choi H., Moletta B., Medina J.H., Izquierdo I. Molecular pharmacological dissection of short- and long-term memory. Cellular and Molecular Neurobiology 2002, 22:269-287.
54. Ji D., Dani J.A. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. Journal of Neurophysiology 2000, 83:2682-2690.
55. Ji D., Lape R., Dani J.A. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 2001, 31:131-141.
56. 2+ entry through non-α7 nicotinic acetylcholine receptors. The European Journal of Neuroscience 2010, 31:463-476.
57. Jones S., Sudweeks S., Yakel J.L. Nicotinic receptors in the brain: correlating physiology with function. Trends in Neurosciences 1999, 22:555-561.
58. Kaduszkiewicz H., Zimmermann T., Beck H.-P., van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005, 331:321-327.
59. Kapai N., Bukanova J., Solntseva E., Skrebitsky V. Donepezil in a narrow concentration range augments control and impaired by β-amyloid peptide hippocampal LTP in NMDAR-independent manner. Cellular and Molecular Neurobiology 2012, 32:219-226.
60. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews. Drug Discovery 2011, 10:698-712.
61. Khiroug L., Giniatullin R., Klein R.C., Fayuk D., Yakel J.L. Functional mapping and Ca2+ regulation of nicotinic acetylcholine receptor channels in rat hippocampal CA1 neurons. Journal of Neuroscience 2003, 23:9024-9031.
62. Klein W.L. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?. Journal of Alzheimer's disease 2013, 33:49-65.
63. Knobloch M., Farinelli M., Konietzko U., Nitsch R.M., Mansuy I.M. Aβ oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. Journal of Neuroscience 2007, 27:7648-7653.
64. Krafft G.A., Klein W.L. ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology 2010, 59:230-242.
65. Kroker K.S., Rast G., Giovannini R., Marti A., Dorner-Ciossek C., Rosenbrock H. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012, 62:1964-1974.
66. Kroker K.S., Rast G., Rosenbrock H. Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP. Neuropharmacology 2011, 61:707-714.
67. Kroker K.S., Rast G., Rosenbrock H. Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP. European Journal of Pharmacology 2011, 671:26-32.
68. Kroker K.S., Rosenbrock H., Rast G. A multi-slice recording system for stable late phase hippocampal long-term potentiation experiments. Journal of Neuroscience Methods 2011, 194:394-401.
69. Lacor P.N., Buniel M.C., Furlow P.W., Sanz Clemente A., Velasco P.T., Wood M., Viola K.L., Klein W.L. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. Journal of Neuroscience 2007, 27:796-807.
70. 1-42 peptide. Journal of Molecular Neuroscience 2005, 27:13-21.
71. 1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Science of the United States of America 1998, 95:6448-6453.
72. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009, 457:1128-1132.
73. Lee K.S., Schottler F., Oliver M., Lynch G. Brief bursts of high-frequency stimulation produce two types of structural change in rat hippocampus. Journal of Neurophysiology 1980, 44:247-258.
74. Leiser S.C., Bowlby M.R., Comery T.A., Dunlop J. A cog in cognition: how the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacology & Therapeutics 2009, 122:302-311.
75. Lendvai B., Kassai F., Szájli A., Némethy Z. α7 Nicotinic acetylcholine receptors and their role in cognition. Brain Research Bulletin 2013, 93:86-96.
76. Levin E.D. α7-Nicotinic receptors and cognition. Current Drug Targets 2012, 13:602-606.
77. Liao D., Scannevin R.H., Huganir R. Activation of silent synapses by rapid activity-dependent synaptic recruitment of AMPA receptors. Journal of Neuroscience 2001, 21:6008-6017.
78. Lin H., Vicini S., Hsu F.C., Doshi S., Takano H., Coulter D.A., Lynch D.R. Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:16661-16666.
79. Lisman J. Actin's actions in LTP-induced synapse growth. Neuron 2003, 38:361-362.
80. Liu Q., Kawai H., Berg D.K. β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:4734-4739.
81. Liu R., Zhang T.T., Wu C.X., Lan X., Du G.H. Targeting the neurovascular unit: development of a new model and consideration for novel strategy for Alzheimer's disease. Brain Research Bulletin 2011, 86:13-21.
82. Look G.C., Jerecic J., Cherbavaz D.B., Pray T.R., Breach J.C., Crosier W.J., Igoudin L., Hironaka C.M., Lowe R.M., McEntee M., Ruslim-Litrus L., Wu H.M., Zhang S., Catalano S.M., Goure W.F., Summa D., Krafft G.A. Discovery of ADDL-targeting small molecule drugs for Alzheimer's disease. Current Alzheimer Research 2007, 4:562-567.
83. Lu W.Y., Man H.Y., Ju W., Trimble W.S., MacDonald J.F., Wang Y.T. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 2001, 29:243-254.
84. Lu Y.F., Kandel E.R., Hawkins R.D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. Journal of Neuroscience 1999, 19:10250-10261.
85. Ma Q.L., Harris-White M.E., Ubeda O.J., Simmons M., Beech W., Lim G.P., Teter B., Frautschy S.A., Cole G.M. Evidence of Aβ and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models. Journal of Neurochemistry 2007, 103:1594-1607.
86. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
87. Malenka R.C., Nicoll R.A. Long-term potentiation - a decade of progress?. Science 1999, 285:1870-1874.
88. Malinow R. AMPA receptor trafficking and long-term potentiation. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 2003, 358:707-714.
89. Mansvelder H.D., McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000, 27:349-357.
90. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995, 269:1692-1696.
91. McKay B.E., Placzek A.N., Dani J.A. Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochemical Pharmacology 2007, 74:1120-1133.
92. Meltzer H.Y., Gawryl M., Ward S., Dgetluck N., Bhuvaneswaran C., Koenig G., Palfreyman M.G., Hilt D.C. EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy. Neuropsychopharmacology 2011, 36(Suppl.):S178.
93. Moreth J., Kroker K.S., Schwanzar D., Schnack C., von Arnim C.A., Hengerer B., Rosenbrock H., Kussmaul L. Globular and protofibrillar Aβ aggregates impair neurotransmission by different mechanisms. Biochemistry 2013, 52:1466-1476.
94. Nimmrich V., Ebert U. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric β-amyloid. Reviews in the Neurosciences 2009, 20:1-12.
95. Nomura I., Takechi H., Kato N. Intraneuronally injected amyloid beta inhibits long-term potentiation in rat hippocampal slices. Journal of Neurophysiology 2012, 107:2526-2531.
96. Ondrejcak T., Wang Q., Kew J.N.C., Virley D.J., Upton N., Anwyl R., Rowan M.J. Activation of α7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents Aβ-mediated inhibition of LTP in the rat hippocampus. European Journal of Pharmacology 2012, 677:63-70.
97. Pang P.T., Lu B. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. Ageing Research Reviews 2004, 3:407-430.
98. Parri H.R., Hernandez C.M., Dineley K.T. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochemical Pharmacology 2011, 82:931-942.
99. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Progress in Neurobiology 2000, 61:75-111.
100. Penney J.B., Maragos W.F., Greenamyre J.T., Debowey D.L., Hollingsworth Z., Young A.B. Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. Journal of Neurology, Neurosurgery and Psychiatry 1990, 53:314-320.
101. Pichat P., Bergis O.E., Terranova J.P., Urani A., Duarte C., Santucci V., Gueudet C., Voltz C., Steinberg R., Stemmelin J., Oury-Donat F., Avenet P., Griebel G., Scatton B. SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) Efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2006, 32:17-34.
102. Pidoplichko V.I., Noguchi J., Areola O.O., Liang Y., Peterson J., Zhang T., Dani J.A. Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. Learning and Memory 2004, 11:60-69.
103. Poorthuis R.B., Goriounova N.A., Couey J.J., Mansvelder H.D. Nicotinic actions on neuronal networks for cognition: general principles and long-term consequences. Biochemical Pharmacology 2009, 78:668-676.
104. Prickaerts J., van Goethem N.P., Chesworth R., Shapiro G., Boess F.G., Methfessel C., Reneerkens O.A., Flood D.G., Hilt D., Gawryl M., Bertrand S., Bertrand D., König G. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 2011, 62:1099-1110.
105. Radcliffe K., Dani J.A. Nicotinic stimulation produces multiple forms of glutamatergic synaptic enhancement. Journal of Neuroscience 1998, 18:7075-7083.
106. Radek R.J., Kohlhaas K.L., Rueter L.E., Mohler E.G. Treating the cognitive deficits of schizophrenia with α4β2 neuronal nicotinic receptor agonists. Current Pharmaceutical Design 2010, 16:309-322.
107. Rahimi F., Shanmugam A., Bitan G. Structure function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Current Alzheimer Research 2008, 5:319-341.
108. Raymond C.R. LTP forms 1 2 and 3: different mechanisms for the long in long-term potentiation. Trends in Neurosciences 2007, 30:167-175.
109. Reed M.N., Hofmeister J.J., Jungbauer L., Welzel A.T., Yu C., Sherman M.A., Lesné S., LaDu M.J., Walsh D.M., Ashe K.H., Cleary J.P. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiology of Aging 2011, 32:1784-1794.
110. Renner M., Lacor P.N., Velasco P.T., Xu J., Contractor A., Klein W.L., Triller A. Deleterious effects of amyloid β oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010, 66:739-754.
111. Reymann K.G., Frey J.U. The late maintenance of hippocampal LTP: requirements, phases, 'synaptic tagging', 'late-associativity' and implications. Neuropharmacology 2007, 52:24-40.
112. Rezvani A.H., Levin E.D. Cognitive effects of nicotine. Biological Psychiatry 2001, 49:258-267.
113. Robichaud A.J. Approaches to palliative therapies for Alzheimer's disease. Current Topics in Medicinal Chemistry 2006, 6:553-568.
114. Role L.W., Berg D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 1996, 16:1077-1085.
115. Sarter M., Parikh V., Howe W.M. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochemical Pharmacology 2009, 78:658-667.
116. Scopes D.I., O'Hare E., Jeggo R., Whyment A.D., Spanswick D., Kim E.M., Gannon J., Amijee H., Treherne J.M. Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity. British Journal of Pharmacology 2012, 167:383-392.
117. Seabrook G.R., Easter A., Dawson G.R., Bowerx B.J. Modulation of long-term potentiation in CA1 region of mouse hippocampal brain slices by GABAA receptor benzodiazepine site ligands. Neuropharmacology 1997, 36:823-830.
118. Séguéla P., Wadiche J., Dineley-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. Journal of Neuroscience 1993, 13:596-604.
119. Selkoe D.J. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behavioural Brain Research 2008, 192:106-113.
120. Sharples C.G.V., Wonnacott S. Neuronal nocotinic receptors. Tocris Reviews 2001, 19.
121. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-β. Nature Neuroscience 2005, 8:1051-1058.
122. Terry A.V., Decker M.W. Neurobiology of nAChRs and cognition: a mini review of Dr Jerry J. Buccafusco's contributions over a 25 year career. Biochemical Pharmacology 2011, 82:883-890.
123. Thomsen M.S., Hansen H.H., Timmerman D.B., Mikkelsen J.D. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Current Pharmaceutical Design 2010, 16:323-343.
124. Toyohara J., Hashimoto K. α7 Nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Journal of Medicinal Chemistry 2010, 4:37-56.
125. Tribollet E., Bertrand D., Marguerat A., Raggenbass M. Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: an autoradiographic study in the rat brain. Neuroscience 2004, 124:405-420.
126. Tyszkiewicz J.P., Yan Z. β-amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. Journal of Neurophysiology 2005, 93:3102-3111.
127. Ulas J., Cotman C.W. Decreased expression of N-methyl-d-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience 1997, 79:973-982.
128. Um J.W., Nygaard H.B., Heiss J.K., Kostylev M.A., Stagi M., Vortmeyer A., Wisniewski T., Gunther E.C., Strittmatter S.M. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nature Neuroscience 2012, 10.1038/nn.3178.
129. Uzun S., Kozumplik O., Folnegovic-Smalc V. Alzheimer's dementia: current data review. Collegium Antropologicum 2011, 35:1333-1337.
130. Vernino S., Rogers M., Radcliffe K.A., Dani J.A. Quantitative measurement of calcium flux through muscle and neuronal nicotinic acetylcholine receptors. Journal of Neuroscience 1994, 14:5514-5524.
131. Viola K.L., Velasco P.T., Klein W.L. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). Journal of Nutrition, Health and Aging 2008, 12:51S-57S.
132. Wallace T.L., Bertrand D. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opinion on Therapeutic Targets 2012, (Epub ahead of print). 10.1517/14728222.2013.736498.
133. Walsh D.M., Selkoe D.J. Aβ oligomers - a decade of discovery. Journal of Neurochemistry 2007, 101:1172-1184.
134. Walsh D.M., Teplow D.B. Alzheimer's disease and the amyloid β-protein. Progress in Molecular Biology and Translational Science 2012, 107:101-124.
135. Welsby P.J., Rowan M.J., Anwyl R. Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP. Neuropharmacology 2007, 53:188-195.
136. Whitehead A., Perdomo C., Pratt R.D., Birks J., Wilcock G.K., Evans J.G. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. International. Journal of Geriatric Psychiatry 2004, 19:624-633.
137. Wilson A.L., Langley L.K., Monley J., Bauer T., Rottunda S., McFalls E., Kovera C., McCarten J.R. Nicotine patches in Alzheimer's disease: pilot study on learning memory, and safety. Pharmacology Biochemistry and Behavior 1995, 51:509-514.
138. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends in Neurosciences 1997, 20:92-98.
139. Youssef I., Florent-Béchard S., Malaplate-Armand C., Koziel V., Bihain B., Olivier J.L., Leininger-Muller B., Kriem B., Oster T., Pillot T. N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiology of Aging 2008, 29:1319-1333.
140. Zeng Y., Zhao D., Xie C.W. Neurotrophins enhance CaMKII activity and rescue Amyloid-β induced deficits in hippocampal synaptic plasticity. Journal of Alzheimer's Disease 2010, 21:823-831.
141. Zhao D., Watson J.B., Xie C.W. Amyloid β prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. Journal of Neurophysiology 2004, 92:2853-2858.
142. Zhu H.C., Wang L.M., Wang M., Song B., Tan S., Teng J.F., Duan D.X. MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1. Brain research bulletin 2012, 88:596-601.